Search tips
Search criteria 


Logo of plosonePLoS OneView this ArticleSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)
PLoS One. 2011; 6(11): e27487.
Published online 2011 November 17. doi:  10.1371/journal.pone.0027487
PMCID: PMC3219663

Overexpression of Bcl2 in Osteoblasts Inhibits Osteoblast Differentiation and Induces Osteocyte Apoptosis

Eliana Saul Furquim Werneck Abdelhay, Editor


Bcl2 subfamily proteins, including Bcl2 and Bcl-XL, inhibit apoptosis. As osteoblast apoptosis is in part responsible for osteoporosis in sex steroid deficiency, glucocorticoid excess, and aging, bone loss might be inhibited by the upregulation of Bcl2; however, the effects of Bcl2 overexpression on osteoblast differentiation and bone development and maintenance have not been fully investigated. To investigate these issues, we established two lines of osteoblast-specific BCL2 transgenic mice. In BCL2 transgenic mice, bone volume was increased at 6 weeks of age but not at 10 weeks of age compared with wild-type mice. The numbers of osteoblasts and osteocytes increased, but osteoid thickness and the bone formation rate were reduced in BCL2 transgenic mice with high expression at 10 weeks of age. The number of BrdU-positive cells was increased but that of TUNEL-positive cells was unaltered at 2 and 6 weeks of age. Osteoblast differentiation was inhibited, as shown by reduced Col1a1 and osteocalcin expression. Osteoblast differentiation of calvarial cells from BCL2 transgenic mice also fell in vitro. Overexpression of BCL2 in primary osteoblasts had no effect on osteoclastogenesis in co-culture with bone marrow cells. Unexpectedly, overexpression of BCL2 in osteoblasts eventually caused osteocyte apoptosis. Osteocytes, which had a reduced number of processes, gradually died with apoptotic structural alterations and the expression of apoptosis-related molecules, and dead osteocytes accumulated in cortical bone. These findings indicate that overexpression of BCL2 in osteoblasts inhibits osteoblast differentiation, reduces osteocyte processes, and causes osteocyte apoptosis.


Bone is a dynamic tissue that is constantly undergoing remodeling by osteoblasts and osteoclasts, and bone volume is determined by the differentiation and function of osteoblasts and osteoclasts. Osteoblasts, which differentiate from multipotent mesenchymal cells, express bone matrix protein genes at different levels depending on the maturity of the cells. Mesenchymal cells and preosteoblasts weakly express Col1a1, but osteoblasts show increased levels. Immature osteoblasts express osteopontin, and mature osteoblasts strongly express osteocalcin. Mature osteoblasts are finally embedded in the bone matrix to become osteocytes. Osteocytes located in lacunae establish an extensive intracellular and extracellular communication system via gap junction-coupled cell processes and canaliculi, through which cell processes pass throughout bone, and the communication system is extended to osteoblasts on the bone surface [1], [2]. The lacunocanalicular network formed by osteocytes is thought to be an ideal mechanosensory system and suitable for mechanotransduction, by which mechanical energy is converted into electrical and/or biochemical signals [3], [4], [5], [6], [7], [8].

Osteoblast apoptosis plays an important role in bone development and maintenance. It is estimated that 60–80% of osteoblasts that originally assembled at the resorption pit die by apoptosis. Further, bone loss caused by sex steroid deficiency, glucocorticoid excess, or aging is caused in part by osteoblast apoptosis, and PTH, bisphosphonate, and calcitonin exert anabolic action on bone by inhibiting osteoblast apoptosis [9], [10], [11], [12], [13], [14], [15], [16]. Bcl2 subfamily proteins, including Bcl2 and Bcl-XL, inhibit apoptosis through prevention of the release of caspase activators from mitochondria by inhibiting Bax subfamily proteins [17]. Thus, bone loss caused by sex steroid deficiency, glucocorticoid excess, or aging might be inhibited by the upregulation of Bcl2; however, the effects of overexpression of Bcl2 in osteoblast differentiation and bone development and maintenance have not been fully investigated.

Osteocyte apoptosis is a relatively common event in both pathological and healthy human bone and osteocyte apoptosis caused by microdamage precedes intracortical remodeling, raising the possibility that the apoptotic process might generate a signal used in targeted osteoclastic bone resorption [8]. Estrogen withdrawal and glucocorticoids induce osteocyte apoptosis, and estrogen and bisphosphonates attenuate osteocyte apoptosis [16], [18], [19]. The message transmitted by osteocyte apoptosis is considered to travel through the canalicular network to the surface of bone tissue and to be sent on to progenitor cells, leading to the initiation signal for remodeling, thereby stimulating the bone resorption/formation cycle [20]. Distinct from osteoblasts, osteocyte apoptosis represents cumulative death because cellular debris cannot be removed by phagocytes until the surrounding bone is resorbed, and TUNEL reactivity is retained in osteocyte lacunae long after osteocyte death [21].

To evaluate the effects of the overexpression of BCL2 in osteoblasts, we examined osteoblast-specific BCL2 transgenic mice. Here, we show that overexpression of BCL2 in osteoblasts inhibited osteoblast differentiation, reduced osteocyte processes, and caused osteocyte apoptosis.

Materials and Methods

Ethics statement

Prior to the study, all experiments were reviewed and approved by the Animal Care and Use Committee of Nagasaki University Graduate School of Biomedical Sciences. (Permit Number: 0906170767-4).


To generate transgenic mice with osteoblasts that express human BCL2, BCL2 cDNA was inserted into the mammalian expression vector pNASSβ (CLONTECH, Shiga, Japan) by replacing the β-galactosidase gene at Not I sites, and the 2.3 kb osteoblast-specific promoter region of mouse Col1a1 [22] was inserted into pNASSβ at EcoRI-XhoI sites. The 2.3 kb Col1a1 promoter was a kind gift from B. de Crombrugghe (University of Texas M. D. Anderson Cancer Center). Transgenic mice were generated as previously described [23], and transgenic lines were maintained against a B6C3H F1 background. Until 2 weeks of age, both genders were used for analyses, but only male mice were used for analyses after 4 weeks of age. Tg(H) were mated with p53+/− mice [24], and p53−/−tg(H) was finally generated. p53+/− mice were a kind gift from M. Katsuki (National Institute for Basic Biology). Prior to the study, all experiments were reviewed and approved by the Animal Care and Use Committee of Nagasaki University Graduate School of Biomedical Sciences.

Histological analysis

Bone histomorphometric analyses were performed as previously described [23]. For assessment of dynamic histomorphometric indices, mice were injected with calcein 6 d and 2 d before sacrifice at a dose of 0.16 mg/10 g body weight. For histological analyses of the long bones, mice were sacrificed and fixed in 4% paraformaldehyde/0.01 M phosphate-buffered saline, and the long bones were decalcified in 10% EDTA (pH 7.4) and embedded in paraffin. Sections (3–7 µm thick) were stained with hematoxylin and eosin (H-E) or stained for TUNEL using the ApopTag® system (Intergen, Burlington, MA), or subjected to immunohistochemistry using monoclonal anti-human BCL2 antibody (Abcam, Cambridge, UK). For the BrdU incorporation study, mice of 2 and 6 weeks of age were injected intraperitoneally with 100 µg BrdU/g body weight and sacrificed 1 hour later. Sections were stained with the BrdU staining kit (Zymed, San Francisco, CA). In the counting of TUNEL-positive or BrdU-positive osteoblastic cells, only cells in the distal primary spongiosa of femurs, which were recognized as osteoblastic cells from their morphology and attachment to the trabecular bone, were counted. Bone canalicular staining (silver impregnation staining) was performed according to the method previously described [25]. Ultrastructural analysis was performed using a transmission electron microscope (H-7100; Hitachi, Tokyo, Japan) as previously described [26]. To observe the three-dimensional ultrastructure of osteocytes, the HCl-collagenase method [27] was applied. The treated specimens were observed under a scanning electron microscope (S-3500N; Hitachi).

Real-time RT-PCR and Western blot analyses

Muscle, connective tissue, and periosteum were removed from femurs and tibiae, and the bones were cut at the metaphyses. After hematopoietic cells in the diaphyses of femurs and tibiae were flushed out with PBS, osteoblast-enriched cells were collected using a micro-intertooth brush (Kobayashi Pharmaceutical Co. Ltd. Osaka, Japan). The remaining bone was used as a source of osteocyte-enriched cells. Nearly complete removal of osteoblasts from the endosteum by the micro-intertooth brush was confirmed using a scanning electron microscope (Miniscope TM-1000; Hitachi). Total RNA was extracted using ISOGEN (Wako, Osaka, Japan), and real-time RT-PCR was performed as previously described [28]. Primer sequences are shown (Table S1). We normalized the values to those of Gapdh. Using osteoblast-enriched or osteocyte-enriched whole-cell lysates, Western blot analysis was performed using the following antibodies: anti-BCL2, anti-p53, anti-Cul1, anti-Bim, anti-Cyclin D1, anti-t-Bid, anti-Bad, and anti-Bcl-XL (BD); anti-Bax, anti-p21, anti-p27, anti-p16, anti-actin (Santa Cruz Biotechnology, Santa Cruz, CA); anti-p57 (Sigma, St. Louis, MO); anti-cleaved caspase-3 (Chemicon, Temecula, CA); anti-Hif-1α (Zymed, San Francisco, CA); and anti-Mcl1 (Abcam).

Micro-CT analysis

Quantitative micro-CT analysis was performed with a micro-CT system (μCT-20; Scanco Medical, Brüttisellen, Switzerland). Data from scanned slices were used for three-dimensional analysis to calculate femoral morphometric parameters. Trabecular bone parameters were measured on a distal femoral metaphysis. Approximately 2.4 mm (0.5 mm from the growth plate) were cranio-caudally scanned and 200 slices in 12 µm increments were made.

Cell culture experiments

Primary osteoblasts were isolated from newborn calvaria by sequential digestion with 0.1% collagenase A and 0.2% dispase. Osteoblastic cells from the third to fifth fraction were pooled and used for MTT assay and osteoblast differentiation. To examine osteoblast differentiation, staining for alkaline phosphatase (ALP) activity and mineralization was performed as previously described [29]. Mineralization was quantified using VHX-1000 (KEYENCE) and Image J. Primary calvarial cells derived from C57BL/6 embryos at embryonic day 18.5 were also prepared by culturing small pieces of calvaria in three-dimensional collagen gel for 10–14 days as described previously [29], and used for the analyses of osteoblast differentiation, apoptosis, and osteoclastogenesis. To examine apoptosis, calvarial cells were infected with EGFP-expressing retrovirus or human BCL2- and EGFP-expressing retrovirus, which was generated by a bicistronic expression vector (human BCL2 internal ribosome entry site (IRES)-EGFP), plated on 8-well chamber slides (Nalge Nunc, Rochester, NY) at a density of 1×104/well, and treated with PBS or 1 mM hydrogen peroxide for 3 hrs after confluence. TUNEL-positive cells were detected using the ApopTag® system (Intergen, Burlington, MA). The co-culture of primary osteoblasts and bone marrow cells was performed as previously described [26]. In all of the retrovirus infection experiments, the amount of retrovirus was adjusted to obtain similar EGFP signals in the EGFP-expressing retrovirus and human BCLl2- and EGFP-expressing retrovirus infections.

Statistical analysis

Statistical analyses were performed using Student's t-test. P<0.05 was considered significant.


Bone mass increased in Bcl2 transgenic mice at 6 weeks but not 10 weeks of age

We established two lines of human BCL2 transgenic mice under the control of mouse 2.3 kb Col1a1 promoter with different expression levels, a transgenic line with low expression of BCL2 (tg(L)) and a transgenic line with high expression of BCL2 (tg(H)) (Fig. 1A, B). Transgene expression was examined by immunohistochemistry at 2 weeks of age, and was specifically detected in osteoblasts and young osteocytes (Fig. 1C, D). We also examined the expression of the transgene in other tissues by real-time RT-PCR. Although the transgene was weakly detected in the skin as previously described [22], it was barely detectable in the brain, heart, lung, stomach, liver, kidney, testis, and muscle (Fig. 1E). We examined the bone phenotypes at a growing stage (6 weeks of age) and an adult stage (10 weeks of age). On micro-computed tomography (micro-CT) analysis at 6 weeks of age, bone volume, trabecular number, and trabecular thickness were increased in tg(L) compared with wild-type mice (Fig. 1F, G). Bone histomorphometric analysis showed that the osteoblast surface was markedly increased in tg(L) compared with wild-type mice at 6 weeks of age (osteoblast surface: wild-type mice; 33.9±9.2%, tg(L); *60.4±5.3%, n = 6–8, *p<0.01); however, the parameters of trabecular bone in tg(L) and tg(H) were comparable to those in wild-type mice at 10 weeks of age on micro-CT analysis (Fig. 1H, I). At 10 weeks of age, peripheral quantitative computed tomography (pQCT) analysis showed that the mineral density of cortical bone was reduced in tg(H) but not in tg(L) compared with that in wild-type mice (Figure S1). Bone histomorphometric analysis at 10 weeks of age showed that the numbers of osteoblasts and osteocytes were increased in both tg(L) and tg(H) compared with those in wild-type mice, but that the bone volume, osteoid thickness, and bone formation rate were not increased in tg(L) and reduced in tg(H) compared with those in wild-type mice, irrespective of the similar levels of osteoclast parameters among wild-type mice, tg(L), and tg(H) (Fig. 1J). The phenotypic differences observed in BCL2 transgenic mice at 6 and 10 weeks of age were likely to be due to the change in transgene expression, because the level of transgene expression at 10 weeks of age was about half of that at 6 weeks of age in real-time RT-PCR analysis (data not shown).

Figure 1
Generation of BCL2 transgenic mice and micro-CT and bone histomorphometric analyses.

Osteoblast proliferation was increased without augmentation of apoptosis and osteoblast differentiation was impaired in BCL2 transgenic mice

As the osteoblast density was increased in BCL2 transgenic mice, we examined the effect of BCL2 on osteoblast proliferation by BrdU labeling. The percentage of BrdU-positive cells was increased mildly in tg(L) and markedly in tg(H) at 2 weeks of age and increased similarly in tg(L) and tg(H) at 6 weeks of age compared with that in wild-type mice at the respective age (Fig. 2A–C, G). We also examined osteoblast apoptosis by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL). Similar percentages of TUNEL-positive osteoblastic cells were observed among wild-type mice, tg(L), and tg(H) (Fig. 2D–F, H).

Figure 2
Analyses of osteoblast proliferation, apoptosis, and differentiation in BCL2 transgenic mice.

As osteoblast proliferation was increased in BCL2 transgenic mice, we examined the expression of cell cycle-related molecules by real-time RT-PCR and Western blot analyses using osteoblast-enriched samples from femurs and tibiae (Fig. 2I, J). The mRNA and protein levels of cyclin D1, p21, and Cul1 were increased and the protein levels of p53, p27, and p16 were increased.

Next, we examined the expression of osteoblast differentiation markers. Real-time RT-PCR analysis showed similar expression levels of Col1a1, osteopontin, and osteocalcin in tg(L), but reductions in Col1a1 and osteocalcin expression and an increase in osteopontin expression in tg(H) compared with the respective levels in wild-type mice at 2 weeks of age (Fig. 2K). Similar results were also obtained by Northern blot analysis at 4 weeks of age and in situ hybridization at 8 weeks of age (Figure S2). These findings indicate that osteoblast differentiation was impaired in tg(H). Since the osteoblast density but neither the bone volume nor bone formation rate were increased in tg(L) and tg(H) at 10 weeks of age (Fig. 1J), osteoblast function should have been impaired in both tg(L) and tg(H).

Overexpression of BCL2 in osteoblasts inhibits osteoblast differentiation and apoptosis but has no effect on osteoclastogenesis in vitro

In contrast to enhanced osteoblast proliferation in BCL2 transgenic mice, overexpression of BCL2 had no effect on osteoblast proliferation in vitro (Figs. 2A–C, G, ,3A).3A). To examine the effect of Bcl2 on osteoblast differentiation, we first introduced BCL2 into primary osteoblasts from wild-type mice by retrovirus and examined ALP activity. ALP activity in BCL2-introduced cells was increased compared with that in EGFP-introduced cells when the cells were seeded at 1.5×104 cells/well, whereas it was reduced compared with that in EGFP-introduced cells when seeded at 5×104 cells/well (Fig. 3B). To investigate why ALP activity was dependent on cell density, we examined the effect of BCL2 on apoptosis in vitro, because cell density is critical for osteoblast differentiation. Overexpression of BCL2 in primary osteoblasts significantly reduced osteoblast apoptosis with or without hydrogen peroxide treatment (Fig. 3C–G). To minimize the effect of BCL2 on apoptosis during culture, primary osteoblasts from tg(H) were seeded at the high concentration (5×104 cells/well). ALP activity, mineralization, and the expressions of ALP and osteocalcin were reduced compared with in wild-type mice (Fig. 3H–J).

Figure 3
Analyses of osteoblast proliferation, apoptosis, and differentiation and osteoclastogenesis in vitro.

To investigate the osteoblast function of supporting osteoclastogenesis, we co-cultured calvarial cells and bone marrow cells. Retroviral introduction of either EGFP or BCL2 into primary osteoblasts showed similar numbers of tartrate-resistant acid phosphatase (TRAP)-positive cells and a similar resorption area in the co-culture (Fig. 3K–R).

Osteocyte apoptosis in BCL2 transgenic mice

Surprisingly, empty lacunae or lacunae containing cell debris were increased in BCL2 transgenic mice, and the increase was already evident in the distal femoral metaphysis of tg(H) at 1 week of age (Figure S3). To examine whether the osteocytes died by apoptosis, we performed TUNEL staining. About 1% of lacunae in the cortical bone at the diaphyses of femurs were TUNEL-positive in wild-type mice from 2 to 10 weeks of age, whereas the corresponding percentage was about 10% in both tg(L) and tg(H) at 2 and 4 weeks of age, 20% in tg(L) and 40% in tg(H) at 5–6 weeks of age, and 50% in tg(L) and 60% in tg(H) at 10 weeks of age (Figs. 4, ,5A).5A). After the death of osteocytes, the lacunae contained only cell debris but TUNEL reactivity was retained in the lacunae (Fig. 4), because the debris of dead osteocytes cannot be eliminated until the surrounding bone is resorbed. Thus, TUNEL-positive lacunae accumulated during bone development. To further confirm that the osteocytes in BCL2 transgenic mice died by apoptosis, we observed them by transmission electron microscopy, which is the most reliable tool for evaluation of the type of cell death (Fig. 5B, C). Apoptotic structural alterations of osteocytes, such as cytoplasmic shrinkage, chromatin condensation, and nuclear disintegration, were observed in the lacunae of the cortical bone of tibiae of BCL2 transgenic mice (Fig. 5C); however, we did not observe cellular swelling, disturbance of plasma membranes and membranes of cytoplasmic organelles, or swollen, electron-lucent nuclei, all of which are features of necrosis. Canaliculi and osteocyte processes were abundant and densely connected in wild-type mice, whereas the numbers of canaliculi and osteocyte processes were reduced depending on the expression levels of the transgene and were sparsely connected in BCL2 transgenic mice (Fig. 5D–I, L, data not shown). Observation by polarized microscopy showed lamellar collagen deposition in the cortical bone of both wild-type mice and tg(L), although the collagen fibers were mildly disorganized in tg(L), probably due to the death of osteocytes (Fig. 5J, K).

Figure 4
Osteocyte apoptosis in cortical bone.
Figure 5
Histological analysis of osteocytes.

Expression of apoptosis-related genes in osteocytes and failure to rescue apoptosis by p53 deletion in BCL2 transgenic mice

In accordance with the appearance of apoptotic cells, p53, Bax, Bim, Noxa, and Vegf were upregulated in the osteocyte-enriched samples from tg(H) compared with the respective levels in those from wild-type mice (Fig. 6A). On Western blot analyses using osteoblast-enriched samples, the protein levels of p53, Bax, Bim, and t-Bid in tg(H) were slightly increased and the protein level of cleaved caspase-3 in tg(H) was similar to the respective level in wild-type mice (Fig. 6B). On Western blot analyses using osteocyte-enriched samples, however, protein levels of p53, HIF-1α, Bax, Bim, t-Bid, and cleaved caspase-3 were apparently increased and that of Mcl1 was decreased in tg(H) compared with the respective level in wild-type mice (Fig. 6C), further supporting the histological observation that osteocytes died by apoptosis. As p53 expression was markedly increased in the osteocytes of BCL2 transgenic mice, we mated tg(H) with p53+/− mice and finally generated p53−/−tg(H) mice (Fig. 6D–G). The deletion of p53 failed to inhibit osteocyte apoptosis in tg(H) (Fig. 6H).

Figure 6
Expression of apoptosis-related molecules and TUNEL staining of cortical bone in p53−/−tg(H).


We analyzed male BCL2 transgenic mice, and osteoblast density was increased in tg(L) and tg(H) but the bone formation rate was similar or reduced in tg(L) and tg(H), respectively, compared with wild-type mice. Although the differentiation stage of osteoblasts was not examined in the previously reported BCL2 transgenic mice, we found that osteoblast differentiation was inhibited in a manner dependent on transgene expression, as shown by the reduction in Col1a1 and osteocalcin expression and the increase in osteopontin expression. Further, the inhibition of osteoblast differentiation was also observed in ex vivo experiments; however, the differentiation of osteoblasts derived from the previous BCL2 transgenic mice was shown to be enhanced in vitro [30]. This controversial result may have been caused by an increase in the cell density of primary osteoblasts from BCL2 transgenic mice compared with wild-type mice during culture, because the frequency of apoptosis in wild-type primary osteoblasts fell to one third by the introduction of BCL2 (Fig. 3G) and the increased cell density accelerated osteoblast differentiation.

Although osteoblast proliferation was not examined in vivo in previously reported BCL2 transgenic mice [31], we showed that osteoblast proliferation was enhanced in BCL2 transgenic mice; however, introduction of BCL2 failed to enhance the proliferation of wild-type primary osteoblasts (Fig. 3A), and primary osteoblasts from previous BCL2 transgenic mice showed similar proliferation to those from wild-type mice [30]. Further, previous reports showed that Bcl2 inhibited cell proliferation by facilitating G0 arrest and delaying G0 to S phase transition in hematopoietic cells and fibroblasts [32], and various groups showed that p27 as well as p130 was elevated in Bcl2-overexpressing cells during arrest [33], [34], [35], [36], although overexpression of Bcl2 in myocytes promoted proliferation [37]. Therefore, BCL2 may have no intrinsic ability to enhance osteoblast proliferation, and it is possible that the population of proliferating osteoblasts was increased by the deceleration of osteoblast differentiation in BCL2 transgenic mice. The upregulation of cyclinD1 and Cul1, which is a component of an ubiquitin ligase complex targeting p21 and p27 [38], [39], in BCL2 transgenic mice may reflect the accumulation of proliferating osteoblasts. Osteoblast apoptosis was not reduced in BCL2 transgenic mice; however, osteoblast apoptosis should have been suppressed in BCL2 transgenic mice because of an increase of proliferating osteoblasts, in which apoptosis would be increased by replication stress [40], and the suppression of apoptosis should have contributed to the increase in the number of proliferating osteoblasts.

A increase in osteocyte apoptosis was not observed in the previous BCL2 transgenic mice [31]. The discrepancy of the osteocyte phenotype may be due to differences in the genetic background because the previous BCL2 transgenic mice were CD-1 outbred mice. We observed an increase in osteocyte apoptosis not only in BCL2 transgenic mice with a B6C3H F1 background but also in those with a C57BL/6 background, which were generated by backcrossing with C57BL/6 mice ten times (data not shown). Outbred mice may have been resistant to osteocyte apoptosis caused by overexpression of BCL2 in osteoblasts. It is also possible that the expression level of the transgene in the previous report was insufficient to induce osteocyte apoptosis.

In our transgenic mice, overexpression of BCL2 in osteoblasts led to a reduction in the number of osteocyte processes. This suggests that Bcl2 alters cytoskeletal organization. Recently, it was reported that Bcl2 is able to form a complex with actin and gelsolin, which functions to decrease gelsolin-severing activity to increase actin polymerization, and to suppress cell adhesion, spreading, and motility [41]. Further, Bcl2 is an independent indicator of a favorable prognosis for all types of early-stage breast cancer [42], [43]. Thus, the reduction in osteocyte processes in BCL2 transgenic mice may show the function of Bcl2, which modulates cytoskeletal reorganization.

The reduction in osteocyte processes in BCL2 transgenic mice would result in a limited supply of oxygen, nutrients, and survival factors to osteocytes. In accordance with this hypothesis, Hif1-α protein, which is stabilized in hypoxia [44], and p53 protein, which is stabilized by hypoxia, nutrient deprivation, and withdrawal of survival factors in addition to DNA damage [45], [46], were markedly increased, and their target genes, including Bax and Noxa, were upregulated in osteocytes of BCL2 transgenic mice. The expression of Mcl-1, which is a key member of the Bcl2 family of pro-survival proteins and undergoes proteasomal-dependent degradation during anoxia and growth factor withdrawal, was reduced in osteocytes [47], [48]. Further, Bim, which is upregulated by FOXO after the withdrawal of growth factors [49], and a truncated form of Bid (t-Bid), which is a product of caspase-8 mediated cleavage of Bid through death receptor signaling [17], increased. The failure to rescue osteocyte apoptosis by p53 deletion also indicates that multiple signaling pathways were involved in osteocyte apoptosis. These findings strongly suggest that osteocyte apoptosis in BCL2 transgenic mice was caused by an insufficient supply of oxygen, nutrients, and survival factors, probably due to the reduction of osteocyte processes.

Our BCL2 transgenic mouse with accumulated dead osteocytes is a useful model to analyze the function of osteocytes because a repair process, which replaces dead osteocytes with new osteocytes by bone resorption and formation, was not evident in the mice irrespective of the massive accumulation of dead osteocytes. The functions of osteocytes in a physiological condition and an unloaded condition were examined using these mice (submitted to another journal). The gradual accumulation of death osteocytes and the reduction in the number of osteocyte processes, which will restrict the secretion of inflammation-inducible molecules to bone marrow, may have limited the repair reaction. We also successfully identified using BCL2 transgenic mice that pyruvate dehydrogenase 4 (Pdk4) is one of the molecules responsible for bone loss in unloading [50].

In conclusion, osteoblast apoptosis is in part responsible for osteoporosis in sex steroid deficiency, glucocorticoid excess and aging, however, BCL2 inhibited osteoblast differentiation, impaired osteoblast function, and reduced the number of osteocyte processes. Thus, our results improve the comprehension of cellular mechanisms involved in osteoporosis.

Supporting Information

Figure S1

pQCT analysis. The cortical bone density in 15 equal cross-divisions from metaphyses to diaphyses of femurs was measured in male wild-type mice (blue circles), tg(L) (red triangles), and tg(H) (yellow circles) of 10 weeks of age. Data are presented as the mean ± SD of 6 mice. *vs. wild-type mice, **p<0.01. pQCT analysis was performed using an XCT Research SA (Stratec Medizintechnick). The mineral density in cortical bone was analyzed using the threshold value, 690 mg/cm3.


Figure S2

Northern blot and in situ hybridization analyses. (A) Northern blot analysis of the bone matrix protein genes including Col1a1, osteopontin, and osteocalcin. RNA was extracted from the femurs of two male BCL2 transgenic mouse lines (tg(L) and tg(H)) and wild-type mice (wt) at 4 weeks of age. Twenty micrograms of RNA was loaded and Gapdh was used as an internal control. (B–J) The expression of Col1a1 (B–D), osteopontin (E–G), and osteocalcin (H–J) in male wild-type mice (B, E, H), tg(L) (C, F, I), and tg(H) (D, G, J) was examined by in situ hybridization at 8 weeks of age. Serial sections from tibiae were used for in situ hybridization and counterstained with methyl green. Scale bars: 0.5 mm.


Figure S3

Histological analysis of BCL2 transgenic mice at 1 week of age. Sections from femurs of wild-type mice (A), tg(L) (B), and tg(H) (C) were stained with H-E, and the cortical bones are shown. Arrows in C indicate the lacunae containing cell debris. Scale bars = 0.1 mm.


Table S1

Primer sequences.



We thank B. de Crombrugghe for the Col1a1 promoter, M. Katsuki for p53+/− mice, N. Kanatani for the generation of BCL2 transgenic mice, and C. Fukuda for secretarial assistance.


Competing Interests: The authors have declared that no competing interests exist.

Funding: This work was supported by grants from the Japanese Ministry of Education, Culture, Sports, Science and Technology, the “Ground-based Research Program for Space Utilization” promoted by the Japan Space Forum, the Nakatomi Foundation, and the President's Discretionary Fund of Nagasaki University, Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.


1. Marks SC, Odgren PR. Structure and development of the skeleton. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of Bone Biology. Second Edition. Vol. 1. London: Academic Press; 2002. pp. 3–15.
2. Aubin EJ, Triffitt TJ. Mesenchymal stem cells and osteoblast differentiation. In: Bilezikian JP, Raisz LG, Rodan GA, editors. Principles of Bone Biology. Second Edition. Vol. 1. London: Academic Press; 2002. pp. 59–81.
3. Martin RB. Does osteocyte formation cause the nonlinear refilling of osteons? Bone. 2000;26(1):71–78. [PubMed]
4. Ehrlich PJ, Lanyon LE. Mechanical strain and bone cell function: a review. Osteoporos Int. 2002;13(9):688–700. [PubMed]
5. Knothe Tate ML. “Whither flows the fluid in bone?” An osteocyte's perspective. J Biomech. 2003;36(10):1409–1424. [PubMed]
6. Burger EH, Klein-Nulend J. Mechanotransduction in bone–role of the lacuno-canalicular network. FASEB J. 1999;13(Suppl):S101–112. [PubMed]
7. Bonewald L, Johnson M. Osteocytes, mechanosensing and Wnt signaling. Bone. 2008;42(4):606–615. [PMC free article] [PubMed]
8. Noble B. The osteocyte lineage. Arch Biochem Biophys. 2008;473(2):106–111. [PubMed]
9. O'Brien CA, Jia D, Plotkin LI, Bellido T, Powers CC, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology. 2004;145(4):1835–1841. [PubMed]
10. Kousteni S, Bellido T, Plotkin LI, O'Brien CA, Bodenner DL, et al. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell. 2001;104(5):719–730. [PubMed]
11. Stanislaus D, Yang X, Liang JD, Wolfe J, Cain RL, et al. In vivo regulation of apoptosis in metaphyseal trabecular bone of young rats by synthetic human parathyroid hormone (1–34) fragment. Bone. 2000;27(2):209–218. [PubMed]
12. Gohel A, McCarthy MB, Gronowicz G. Estrogen prevents glucocorticoid-induced apoptosis in osteoblasts in vivo and in vitro. Endocrinology. 1999;140(11):5339–5347. [PubMed]
13. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102(2):274–282. [PMC free article] [PubMed]
14. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas SC, et al. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999;104(10):1363–1374. [PMC free article] [PubMed]
15. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest. 1999;104(4):439–446. [PMC free article] [PubMed]
16. Tomkinson A, Reeve J, Shaw RW, Noble BS. The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. J Clin Endocrinol Metab. 1997;82(9):3128–3135. [PubMed]
17. Tsujimoto Y. Cell death regulation by the Bcl-2 protein family in the mitochondria. Journal of Cellular Physiology. 2003;195(2):158–167. [PubMed]
18. Weinstein RS, Nicholas RW, Manolagas SC. Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab. 2000;85(8):2907–2912. [PubMed]
19. Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem. 2005;280(8):7317–7325. [PubMed]
20. Rochefort GY, Pallu S, Benhamou CL. Osteocyte: the unrecognized side of bone tissue. Osteoporos Int. 2010;21(9):1457–1469. [PubMed]
21. Jilka RL, Weinstein RS, Parfitt AM, Manolagas SC. Quantifying osteoblast and osteocyte apoptosis: challenges and rewards. J Bone Miner Res. 2007;22(10):1492–1501. [PubMed]
22. Rossert J, Eberspaecher H, de Crombrugghe B. Separate cis-acting DNA elements of the mouse pro-alpha 1(I) collagen promoter direct expression of reporter genes to different type I collagen-producing cells in transgenic mice. J Cell Biol. 1995;129(5):1421–1432. [PMC free article] [PubMed]
23. Liu W, Toyosawa S, Furuichi T, Kanatani N, Yoshida C, et al. Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J Cell Biol. 2001;155(1):157–166. [PMC free article] [PubMed]
24. Gondo Y, Nakamura K, Nakao K, Sasaoka T, Ito K, et al. Gene replacement of the p53 gene with the lacZ gene in mouse embryonic stem cells and mice by using two steps of homologous recombination. Biochem Biophys Res Commun. 1994;202(2):830–837. [PubMed]
25. Kusuzaki K, Kageyama N, Shinjo H, Takeshita H, Murata H, et al. Development of bone canaliculi during bone repair. Bone. 2000;27(5):655–659. [PubMed]
26. Maruyama Z, Yoshida CA, Furuichi T, Amizuka N, Ito M, et al. Runx2 determines bone maturity and turnover rate in postnatal bone development and is involved in bone loss in estrogen deficiency. Dev Dyn. 2007;236(7):1876–1890. [PubMed]
27. Ejiri S, Ozawa H. Scanning electron microscopic observations of rat tibia using the HCl-collagenase method. Arch Histol Jpn. 1982;45(4):399–404. [PubMed]
28. Yoshida CA, Yamamoto H, Fujita T, Furuichi T, Ito K, et al. Runx2 and Runx3 are essential for chondrocyte maturation, and Runx2 regulates limb growth through induction of Indian hedgehog. Genes Dev. 2004;18(8):952–963. [PubMed]
29. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, et al. Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell. 1997;89(5):755–764. [PubMed]
30. Zhang W, Pantschenko AG, McCarthy MB, Gronowicz G. Bone-Targeted Overexpression of Bcl-2 Increases Osteoblast Adhesion and Differentiation and Inhibits Mineralization In Vitro. Calcified Tissue International. 2007;80(2):111–122. [PubMed]
31. Pantschenko AG, Zhang W, Nahounou M, McCarthy MB, Stover ML, et al. Effect of Osteoblast-Targeted Expression of Bcl-2 in Bone: Differential Response in Male and Female Mice. Journal of Bone and Mineral Research. 2005;20(8):1414–1429. [PubMed]
32. Zinkel S, Gross A, Yang E. BCL2 family in DNA damage and cell cycle control. Cell Death and Differentiation. 2006;13(8):1351–1359. [PubMed]
33. Gerald P, Linette YL, Kevin R, Stanley JK. Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. Proc Natl Acad Sci USA. 1996;93:9545–9552. [PubMed]
34. Brady HJ, Gil-Gomez G, Kirberg J, Berns AJ. Bax alpha perturbs T cell development and affects cell cycle entry of T cells. The EMBO Journal. 1996;15:6991–7001. [PubMed]
35. Evan FL, Jay W, Qi-Zhi W, Teodora S, Amy S, Petrie HT. Bcl-2-Induced Changes in E2F Regulatory Complexes Reveal the Potential for Integrated Cell Cycle and Cell Death Functions1. Journal of Immunology. 1999;162:5374–5379. [PubMed]
36. Vairo G, Soos TJ, Upton TM, Zalvide J, DeCaprio JA, et al. Bcl-2 retards cell cycle entry through p27(Kip1), pRB relative p130, and altered E2F regulation. Mol Cell Biol. 2000;20(13):4745–4753. [PMC free article] [PubMed]
37. Limana F, Urbanek K, Chimenti S, Quaini F, Leri A, et al. bcl-2 overexpression promotes myocyte proliferation. Proc Natl Acad Sci U S A. 2002;99(9):6257–6262. [PubMed]
38. Bornstein G. Role of the SCFSkp2 Ubiquitin Ligase in the Degradation of p21Cip1 in S Phase. Journal of Biological Chemistry. 2003;278(28):25752–25757. [PubMed]
39. O'Hagan RC. Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression. Genes & Development. 2000;14(17):2185–2191. [PubMed]
40. Bartek J, Lukas J. DNA damage checkpoints: from initiation to recovery or adaptation. Current Opinion in Cell Biology. 2007;19(2):238–245. [PubMed]
41. Ke H, Parron VI, Reece J, Zhang JY, Akiyama SK, et al. BCL2 inhibits cell adhesion, spreading, and motility by enhancing actin polymerization. Cell Research. 2010;20(4):458–469. [PMC free article] [PubMed]
42. Callagy GM, Webber MJ, Pharoah PDP, Caldas C. Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer. 2008;8(1):153. [PMC free article] [PubMed]
43. Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, et al. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer. 2010;103(5):668–675. [PMC free article] [PubMed]
44. Fels DR, Koumenis C. HIF-1alpha and p53: the ODD couple? Trends Biochem Sci. 2005;30(8):426–429. [PubMed]
45. Hammond EM, Giaccia AJ. The role of p53 in hypoxia-induced apoptosis. Biochem Biophys Res Commun. 2005;331(3):718–725. [PubMed]
46. Levine AJ, Feng Z, Mak TW, You H, Jin S. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. Genes Dev. 2006;20(3):267–275. [PubMed]
47. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen Synthase Kinase-3 Regulates Mitochondrial Outer Membrane Permeabilization and Apoptosis by Destabilization of MCL-1. Molecular Cell. 2006;21(6):749–760. [PubMed]
48. Brunelle JK, Shroff EH, Perlman H, Strasser A, Moraes CT, et al. Loss of Mcl-1 protein and inhibition of electron transport chain together induce anoxic cell death. Mol Cell Biol. 2007;27(4):1222–1235. [PMC free article] [PubMed]
49. Gilley J, Coffer PJ, Ham J. FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol. 2003;162(4):613–622. [PMC free article] [PubMed]
50. Wang Y, Liu W, Masuyama R, Fukuyama R, Ito M, et al. Pyruvate dehydrogenase kinase 4 induces bone loss at unloading by promoting osteoclastogenesis. Bone. 2011 In press. [PubMed]

Articles from PLoS ONE are provided here courtesy of Public Library of Science